ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective

T. Koessler*, M. Alsina, D. Arnold, I. Ben-Aharon, M. Collienne, M. P. Lutz, C. Neuzillet, R. Obermannova, M. Peeters, F. Sclafani, E. Smyth, J. W. Valle, A. D. Wagner, L. Wyrwicz, E. Fontana, M. Moehler

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.

Original languageEnglish
Article number100392
JournalESMO Open
Volume7
Issue number2
DOIs
StatePublished - Apr 2022
Externally publishedYes

Funding

FundersFunder number
Celgene and Nucana
EORTC Cancer Research Fund
Gastrointestinal Tract Cancer Group
Speakers Bureau for Imaging Equipment Limited
Wren Laboratories
Bristol-Myers Squibb
Eli Lilly and Company
Merck
Roche
Boehringer Ingelheim
Servier
Swiss Cancer Research Foundation

    Keywords

    • colorectal cancer
    • neuroendocrine tumours
    • oesophagus cancer
    • pancreatic cancer
    • stomach cancer

    Fingerprint

    Dive into the research topics of 'ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective'. Together they form a unique fingerprint.

    Cite this